A dedicated University of Wisconsin–Madison clinician, educator, advocate and researcher, Renata Laxova, professor emerita of medical genetics and pediatrics, passed away recently after a brief illness. She was 89.
A team of researchers at the University of Wisconsin–Madison is part of a new multi-institution effort to better understand Alzheimer’s disease in adults with Down syndrome. Adults with Down syndrome are at high risk for …
A peek into a collection of newspaper clippings about Ludell Swenson reveals the life of an extraordinarily accomplished person: marathoner, competitive tournament bowler, outspoken social services advocate. But what stands out the most is his …
Congratulations to Aviad Hai, assistant professor of biomedical engineering and a Waisman affiliate, on being selected as a 2020 National Institutes of Health Director’s New Innovator Award.
If you’ve ever seen a graphical representation of a sound, you are probably familiar with what it looks like: hundreds of steep, tightly packed peaks and valleys, all of different heights, moving above and below a common line of symmetry that cuts horizontally through the middle. “When a sound travels through the air, it basically sets the molecules around us in motion, using sound pressure to create sort of a wave,” says Waisman researcher Michaela Warnecke, PhD.
The mature brain is infamously bad at repairing itself following damage like that caused by trauma or strokes, or from degenerative diseases like Parkinson’s. Stem cells, which are endlessly adaptable, have offered the promise of better neural repair. But the brain’s precisely tuned complexity has stymied the development of clinical treatments.
Su-Chun Zhang, MD, PhD, the Steenbock Professor in Behavioral and Neural Sciences at the University of Wisconsin-Madison and Waisman Center investigator, is part of an interdisciplinary team of researchers selected by the Aligning Science Across Parkinson’s (ASAP) initiative to receive $9 million over three years for the “Parkinson5D: Deconstructing Proximal Disease Mechanisms Across Cells, Space and Progression” or PD5D project.
Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.
As a third year graduate student in school psychology at the University of South Carolina, Lindsay McCary, PhD, was looking for a new advisor to help her with her dissertation. At the time, Jane Roberts, PhD, had just joined the Department of Psychology and had some data available on younger children with the genetic disorder fragile X syndrome (FXS). McCary was immediately fascinated by the new professor’s research because it integrated both behavioral and physiological data to examine an individual’s observable characteristics.
The Friends of the Waisman hosts this annual event for members of the Friends organization; community supporters of the Waisman Center; and Waisman Center faculty, staff, and students. The 2020 Awards were presented at a virtual meeting on August 18 2020.